{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=carboplatin&page=47", "query": { "intervention": "carboplatin", "page": 47 }, "page_size": 10 }, "pagination": { "page": 47, "page_size": 10, "total_count": 1996, "total_pages": 200, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=carboplatin&page=48&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=carboplatin&page=46&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-02T16:36:28.798Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02272790", "title": "Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation" ], "interventions": [ { "name": "Adavosertib", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "PLD", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "FEMALE", "summary": "18 Years to 130 Years · Female only" }, "enrollment_count": 95, "start_date": "2015-01-30", "completion_date": "2023-03-08", "has_results": true, "last_update_posted_date": "2023-10-03", "last_synced_at": "2026-11-02T16:36:28.798Z", "location_count": 18, "location_summary": "Gilbert, Arizona • Tucson, Arizona • La Jolla, California + 14 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02272790" }, { "nct_id": "NCT06236438", "title": "Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Livmoniplimab", "type": "DRUG" }, { "name": "Budigalimab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 167, "start_date": "2024-04-10", "completion_date": "2031-10", "has_results": false, "last_update_posted_date": "2026-10-19", "last_synced_at": "2026-11-02T16:36:28.798Z", "location_count": 19, "location_summary": "La Jolla, California • Pembroke Pines, Florida • Winter Haven, Florida + 16 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Pembroke Pines", "state": "Florida" }, { "city": "Winter Haven", "state": "Florida" }, { "city": "Athens", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT06236438" }, { "nct_id": "NCT00005976", "title": "Pyrazoloacridine Plus Carboplatin in Treating Patients With Recurrent Glioma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Brain and Central Nervous System Tumors" ], "interventions": [ { "name": "carboplatin", "type": "DRUG" }, { "name": "pyrazoloacridine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2000-05", "completion_date": "2007-04", "has_results": false, "last_update_posted_date": "2013-06-03", "last_synced_at": "2026-11-02T16:36:28.798Z", "location_count": 22, "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Peoria, Illinois + 19 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Peoria", "state": "Illinois" }, { "city": "Urbana", "state": "Illinois" }, { "city": "Cedar Rapids", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005976" }, { "nct_id": "NCT02453282", "title": "Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-Small-Cell Lung Carcinoma NSCLC" ], "interventions": [ { "name": "MEDI4736 (Durvalumab)", "type": "BIOLOGICAL" }, { "name": "MEDI4736 (Durvalumab)+Tremelimumab", "type": "BIOLOGICAL" }, { "name": "Paclitaxel + Carboplatin", "type": "DRUG" }, { "name": "Gemcitabine + Cisplatin", "type": "DRUG" }, { "name": "Gemcitabine + Carboplatin", "type": "DRUG" }, { "name": "Pemetrexed + Cisplatin", "type": "DRUG" }, { "name": "Pemetrexed + Carboplatin", "type": "DRUG" }, { "name": "Tremelimumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 1118, "start_date": "2015-07-21", "completion_date": "2026-12-31", "has_results": true, "last_update_posted_date": "2026-08-06", "last_synced_at": "2026-11-02T16:36:28.798Z", "location_count": 35, "location_summary": "Scottsdale, Arizona • Tucson, Arizona • Yuma, Arizona + 28 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Yuma", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Fullerton", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02453282" }, { "nct_id": "NCT02289690", "title": "Dose Escalation and Double-blind Study of Veliparib in Combination With Carboplatin and Etoposide in Treatment-naive Extensive Stage Disease Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Small Cell Lung Cancer" ], "interventions": [ { "name": "Veliparib", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 221, "start_date": "2014-10-13", "completion_date": "2019-04-17", "has_results": true, "last_update_posted_date": "2020-05-14", "last_synced_at": "2026-11-02T16:36:28.798Z", "location_count": 9, "location_summary": "Scottsdale, Arizona • Aurora, Colorado • Atlanta, Georgia + 6 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02289690" }, { "nct_id": "NCT00190710", "title": "A Trial of Carboplatin and Gemcitabine Versus Gemcitabine Alone in Patients With Non-Small-Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 242, "start_date": "2004-03", "completion_date": "2007-08", "has_results": false, "last_update_posted_date": "2007-11-14", "last_synced_at": "2026-11-02T16:36:28.798Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00190710" }, { "nct_id": "NCT06875310", "title": "A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "Adagrasib", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mirati Therapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 630, "start_date": "2025-04-24", "completion_date": "2032-04-30", "has_results": false, "last_update_posted_date": "2026-10-27", "last_synced_at": "2026-11-02T16:36:28.798Z", "location_count": 46, "location_summary": "Birmingham, Alabama • Springdale, Arkansas • Fullerton, California + 42 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Fullerton", "state": "California" }, { "city": "Loma Linda", "state": "California" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06875310" }, { "nct_id": "NCT00896181", "title": "Phase 2 Sequential and Concurrent Chemoradiation for Advanced Nasopharyngeal Carcinoma (NPC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Stage II Lymphoepithelioma of the Nasopharynx", "Stage II Squamous Cell Carcinoma of the Nasopharynx", "Stage III Lymphoepithelioma of the Nasopharynx", "Stage III Squamous Cell Carcinoma of the Nasopharynx", "Stage IV Lymphoepithelioma of the Nasopharynx", "Stage IV Squamous Cell Carcinoma of the Nasopharynx" ], "interventions": [ { "name": "docetaxel", "type": "DRUG" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "fluorouracil", "type": "DRUG" }, { "name": "3-dimensional conformal radiation therapy", "type": "RADIATION" }, { "name": "intensity-modulated radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 26, "start_date": "2008-12-10", "completion_date": "2020-12", "has_results": true, "last_update_posted_date": "2021-04-06", "last_synced_at": "2026-11-02T16:36:28.798Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00896181" }, { "nct_id": "NCT00596830", "title": "Carboplatin And Paclitaxel With Or Without CP-751, 871 (An IGF-1R Inhibitor) For Advanced NSCLC Of Squamous, Large Cell And Adenosquamous Carcinoma Histology", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Carcinoma, Squamous Cell", "Carcinoma, Adenosquamous", "Carcinoma, Large Cell", "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "CP-751,871 (Figitumumab)", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 681, "start_date": "2008-04", "completion_date": "2012-09", "has_results": true, "last_update_posted_date": "2014-01-13", "last_synced_at": "2026-11-02T16:36:28.798Z", "location_count": 169, "location_summary": "Florence, Alabama • Huntsville, Alabama • Muscle Shoals, Alabama + 133 more", "locations": [ { "city": "Florence", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Muscle Shoals", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00596830" }, { "nct_id": "NCT02027428", "title": "Safety and Efficacy Study of Abraxane as Maintenance Treatment After Abraxane Plus Carboplatin in 1st Line Stage IIIB / IV Squamous Cell Non-small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Squamous Cell Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "Abraxane (Induction)", "type": "DRUG" }, { "name": "Carboplatin (Induction)", "type": "DRUG" }, { "name": "Abraxane (Maintenance)", "type": "DRUG" }, { "name": "Best Supportive Care (Maintenance)", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 427, "start_date": "2014-02-11", "completion_date": "2019-08-01", "has_results": true, "last_update_posted_date": "2020-08-17", "last_synced_at": "2026-11-02T16:36:28.798Z", "location_count": 91, "location_summary": "Huntsville, Alabama • Glendale, Arizona • Tucson, Arizona + 73 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02027428" } ] }